logo en

logoinserm

logo ups

labo

Next seminars :

No events

Intranet access

Cyclic nucleotide signalling and cardiovascular pathophysiology

 

VANDECASTEELE Grégoire, DR2 Inserm : Team leader
FISCHMEISTER Rodolphe, DRCE Inserm : Team leadere2-fig1
BRENNER Catherine, DR2 Cnrs
LEBLAIS Véronique, PU UPSud
LEROY Jérôme, MCU UPSud
MANOURY Boris, MCU UPSud
ALGALARRONDO Vincent, MCU-PH UPSud
MIKA Delphine, CR Inserm
PIDOUX Guillaume, CR Inserm
VARIN Audrey, IE UPSud
CRUETTE Manon, CDD IE UPSud
PEYRE Félix, CDD IE UPSud
RIDOUX Audrey, CDD IE UPSud
BARTHE Marion, PhD Student
BEDIOUNE Ibrahim, PhD Student
BOUADJEL Kaouter, PhD Student
BOURCIER Aurélia, PhD Student
DEFLERS Carole, PhD Student
IDRES Sarah, PhD Student
LIU Dawei, PhD Student
MARGARIA Jean Piero, PhD Student
WANG Zhenyu, PhD Student
ZHANG Liang, PhD Student

The cyclic nucleotides (CN) cAMP and cGMP participate in the main regulations of cardiac function. They act as second messengers for sympathetic and parasympathetic systems, nitric oxide (NO) and natriuretic peptides. CN may exert beneficial or deleterious effects on the heart, depending on the duration of the stimulation. Acute elevation of CN regulate cardiac excitation-contraction coupling. However, chronic elevation of cAMP contributes to the development of cardiac hypertrophy and progression to heart failure (HF), while cGMP possesses anti-hypertrophic properties. Our work of the last four years has been dedicated to understanding the intracellular organization of CN pathways, which we found are highly compartmentalized, and the changes occurring in pathophysiological situations. The general objective is to understand the molecular mechanisms responsible for the homeostasis of these two second messengers and the functional consequences for cellular and cardiac function. We developed novel electrophysiological and imaging techniques to record simultaneously cyclic nucleotide changes and key functional parameters of the cardiac cell.

e2-fig2